Evidence-based Medicine
Perspective: EBM’s Six Dangerous Words
6 May, 2020 | 03:37h | UTCEBM’s Six Dangerous Words – JAMA
Perspective: Treatments Can Harm
6 May, 2020 | 03:38h | UTCTreatments can harm – Evidently Cochrane
Related: Treatments can harm – Students 4 Best Evidence (commentary and EBM resource) AND Patients’ Expectations of the Benefits and Harms of Treatments, Screening, and Tests: A Systematic Review – JAMA Internal Medicine AND If Patients Only Knew How Often Treatments Could Harm Them – The New York Times
Randomized Clinical Trials and COVID-19: Managing Expectations
5 May, 2020 | 04:56h | UTCRandomized Clinical Trials and COVID-19: Managing Expectations – JAMA
COVID-19: Out-of-control Science and Bypassing Science-based Medicine
5 May, 2020 | 05:04h | UTCCOVID-19: Out-of-control science and bypassing science-based medicine – Science Based Medicine
Related: Covid-19 — A Reminder to Reason – New England Journal of Medicine AND Pandemic Science Out of Control – Issues in Science and Technology AND Science Has an Ugly, Complicated Dark Side. And the Coronavirus Is Bringing It Out – Mother Jones AND Against pandemic research exceptionalism – Science AND In Defense of Evidence-Based Medicine for the Treatment of COVID-19 ARDS – Annals of the American Thoracic Society
Opinion: Pregnant Women Should be Given the Opportunity to be Included in Clinical Trials for COVID-19
3 May, 2020 | 21:51h | UTC“We recommend and urge the scientific community and professional societies that, without clear justification for exclusion, pregnant women should be given the opportunity to be included in clinical trials for COVID-19 based on the concepts of justice, equity, autonomy, and informed consent.”
Treatment Considerations for COVID-19: A Critical Review of the Evidence
1 May, 2020 | 03:20h | UTC
Perspective: Urging Caution on Remdesivir
1 May, 2020 | 03:07h | UTCUrging Caution On Remdesivir – Forbes
Related: About Remdesivir and About “Game-Changers” – Science Translational Medicine AND Conflicting Remdesivir Trial Results Released; Experts Urge More Research – Health Policy Watch AND Is remdesivir a miracle drug to cure coronavirus? Don’t get your hopes up yet – The Conversation AND PulmCrit- First placebo-controlled RCT on remdesivir for COVID-19 – PulmCrit AND Remdesivir: the antiviral drug is being touted as a possible coronavirus treatment – but will it work? – The Guardian
“While I have enormous respect for the Institutes and their leaders, releasing the preliminary news without sharing the data behind it is highly irresponsible.”
Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
30 Apr, 2020 | 04:31h | UTCCommentaries: First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed – The Lancet AND Expert reaction to trial of remdesivir in adults – Science Media Centre
See also: [Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
Related Commentary on Twitter
With all the hype about Remdesivir today @TheLancet has decided to lift the embargo and release this placebo-controlled multicenter study done in China that showed no benefit https://t.co/ZdmKfnWLyw
— Carlos del Rio (@CarlosdelRio7) April 29, 2020
[Not Published Yet] NIH Study Shows Remdesivir Accelerates Recovery from Advanced COVID-19
30 Apr, 2020 | 04:28h | UTCCommentaries: Hopes rise on coronavirus drug remdesivir – Nature AND The COVID-19 research news rollercoaster is running again: STAT News + Gilead’s remdesivir – HealthNews Review
See also: Randomized Trial: Remdesivir Not Beneficial for Adults with Severe COVID-19
Perspective: Covid-19 — A Reminder to Reason
30 Apr, 2020 | 04:15h | UTCCovid-19 — A Reminder to Reason – New England Journal of Medicine
Science Has an Ugly, Complicated Dark Side. And the Coronavirus Is Bringing It Out
30 Apr, 2020 | 04:10h | UTCScience Has an Ugly, Complicated Dark Side. And the Coronavirus Is Bringing It Out – Mother Jones
Perspective: Pandemic Science Out of Control
29 Apr, 2020 | 05:20h | UTCPandemic Science Out of Control – Issues in Science and Technology
Related Commentary on Twitter
"Especially in times of crisis, statistically meaningless, methodologically shoddy, and even fraudulent research can find a receptive audience in desperate patients, credulous doctors, and uninformed journalists."
@JeanneLenzer1 & @ShannonBrownlee https://t.co/Jdw3nT3Z8E— Issues in Science and Technology (@ISSUESinST) April 28, 2020
Perspective: Pseudoscience and COVID-19 — We’ve Had Enough Already
28 Apr, 2020 | 04:35h | UTCPseudoscience and COVID-19 — we’ve had enough already – Nature
Which Epidemiologist do you Believe? The Debate About Lockdown is Not a Contest Between Good and Evil
28 Apr, 2020 | 04:33h | UTCWhich epidemiologist do you believe? – UnHeard
“The debate about lockdown is not a contest between good and evil”
Perspective: Scientists Who Express Different Views on Covid-19 Should Be Heard, not Demonized
28 Apr, 2020 | 04:30h | UTCScientists who express different views on Covid-19 should be heard, not demonized – STAT
Twitter-based Learning for Continuing Medical Education? A New Perspective for a Paradigm Shift in Medical Education, Accelerated by COVID-19
28 Apr, 2020 | 04:28h | UTCRelated: How Twitter is Changing Medical Research (texts on the subject)
COVID-19 Clinical Trials Registry: A Real-time Dashboard of Clinical Trials for COVID-19
26 Apr, 2020 | 21:38h | UTCA real-time dashboard of clinical trials for COVID-19 – The Lancet
See the platform: COVID-19 clinical trials registry
Related Commentary on Twitter
NEW—A real-time dashboard of clinical trials for #COVID19
"An urgent need exists to track clinical trials, avoid unnecessary duplication of efforts, & understand what trials are being done & where"
Correspondence @LancetDigitalH from K Thorlund et al https://t.co/f18UkjSeWU pic.twitter.com/RegM7DJRkP
— The Lancet (@TheLancet) April 25, 2020
Editorial: Preprint Servers: A ‘Rush to Publish’ or ‘Just in Time Delivery’ for Science?
26 Apr, 2020 | 21:23h | UTCPreprint servers: a ‘rush to publish’ or ‘just in time delivery’ for science? – Thorax
Perspective: Against Pandemic Research Exceptionalism
24 Apr, 2020 | 03:39h | UTCAgainst pandemic research exceptionalism – Science
“Crises are no excuse for lowering scientific standards.”
A Skeptic’s Guide To Ecologic Studies During A Pandemic
24 Apr, 2020 | 03:34h | UTCA Skeptic’s Guide To Ecologic Studies During A Pandemic – Forbes
Related: BCG Against Coronavirus: Less Hype And More Evidence, Please – Forbes
Perspective: In Defense of Evidence-Based Medicine for the Treatment of COVID-19 ARDS
24 Apr, 2020 | 03:36h | UTC
Podcast: Twitter, Social Media and Digital Scholarship in Medicine
24 Apr, 2020 | 03:25h | UTC#209 LIVE! Twitter, Social Media and Digital Scholarship – The Curbsiders Internal Medicine Podcast
See also: Episode List
Richard Lehman’s Covid-19 Reviews—20 April 2020
22 Apr, 2020 | 08:50h | UTCRichard Lehman’s covid-19 reviews, 20 April 2020 – The BMJ Opinion
“In this weekly round-up, Richard Lehman looks at a personal selection of articles of relevance to clinicians dealing with covid-19”.
Editorial: Modelling the Pandemic
22 Apr, 2020 | 08:48h | UTCModelling the pandemic – The BMJ
Related: Predictive Mathematical Models of the COVID-19 Pandemic (other commentaries on the subject)
“Over-reliance on modelling leads to missteps and blind spots in our response”
Randomized Trial: Twitter Promotion Increases Citation Rates of Cardiovascular Articles
21 Apr, 2020 | 07:53h | UTC